Bluejay Diagnostics (NASDAQ:BJDX) Issues Quarterly Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) released its quarterly earnings results on Wednesday. The company reported ($1.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88, FiscalAI reports.

Bluejay Diagnostics Stock Down 1.0%

BJDX stock traded down $0.01 during mid-day trading on Friday, hitting $1.05. 63,772 shares of the company were exchanged, compared to its average volume of 2,485,926. Bluejay Diagnostics has a 12-month low of $0.83 and a 12-month high of $16.68. The firm has a market capitalization of $1.08 million, a P/E ratio of -0.09 and a beta of 0.89. The business has a fifty day simple moving average of $2.16 and a 200-day simple moving average of $2.21.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BJDX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. Wall Street Zen upgraded Bluejay Diagnostics to a “sell” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Insider Activity at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt acquired 64,047 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average price of $1.51 per share, with a total value of $96,710.97. Following the transaction, the insider owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. This trade represents a 101.75% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.